A Phase 1/2 interventional study of XL184 and erlotinib in Carcinoma, Non-Small-Cell Lung, sponsored by Exelixis. Completed at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by Exelixis · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing cabozantinib in Carcinoma, Non-Small-Cell Lung — 3 open to participants now, 6 under way, none of them phase 3. cabozantinib · Carcinoma, Non-Small-Cell Lung.
Among the 16 studies testing cabozantinib in Carcinoma, Non-Small-Cell Lung, this one is the 6th largest by enrollment, is the only one that started in 2008, is one of 2 in phase 1/2, and was the 1st registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →3 of the 16 studies testing cabozantinib in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:
University of Illinois at Chicago · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Jun Zhang, MD, PhD · Sites in United States
Ages 18+
By country, each count listing its studies:
cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, cabozantinib is the treatment under test here. Read study by study →
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 1
First in 2008; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 92 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 39 across the 16 interventional studies. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 16 have an industry lead sponsor. The 10 most frequent:
Exelixis is the lead sponsor of 57 studies on the registry; 11 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Exelixis has 9 studies filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
1 of the studies testing cabozantinib in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01639508Memorial Sloan Kettering Cancer CenterCabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing cabozantinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study consisted of a Phase 1 dose escalation/dose de-escalation portion to determine a safe and tolerable combination dose(s) of cabozantinib and erlotinib, and a Phase 2 Simon optimal 2-stage design portion with randomized assignment of subjects in an equal ratio to determine the objective response rate (ORR) of cabozantinib with or without erlotinib in subjects with non-small cell lung cancer (NSCLC) who have progressed after responding to treatment with erlotinib. The doses of cabozantinib used in this study were based on the salt weight, not the freebase weight.
Inclusion Criteria-Phase 1:
Exclusion Criteria-Phase 1:
Inclusion Criteria-Phase 2
Exclusion Criteria-Phase 2
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Escalating doses of XL184 + erlotinib
Drug: XL184 · Drug: erlotinib
XL184 + erlotinib (dose determined from Phase 1 portion of study)
Drug: XL184 · Drug: erlotinib
XL184 administered as a single agent
Drug: XL184
Phase 1: Duration of Exposure of Cabozantinib With Erlotinib
Treatment duration was defined as the number of days from the first dose to the last dose (measured in weeks), including any days of treatment interruption that occurred before the last dose of study drug.
Time frame: From initial dose up to 160 weeks
Phase 2: Objective Response Rate (ORR)
Objective Response Rate is defined as the number of participants for whom the best overall response is complete (CR) or partial response (PR) confirmed by repeat assessments no less than four weeks after the criteria for the initial response were first met.
Time frame: From initial dose up to 72 weeks
Phase 2: Duration of Response (DOR) in Participants With a CR or PR
DOR was defined as the time interval from the first documentation of CR or PR to the earlier of the first documentation of definitive disease progression or death from any cause.
Time frame: From initial dose up to 72 weeks
Phase 2: Progression-Free Survival (PFS)
Progression-free survival is defined as the time from first dose of cabozantinib to disease progression per protocol-defined criteria or death due to any cause, whichever occurs first.
Time frame: From initial dose up to 72 weeks
| Milestone | Phase 1-Cohort 1 | Phase 1-Cohort 2A | Phase 1-Cohort 2B | Phase 1-Cohort 3A | Phase 1-Cohort 4A | Phase 2-cabozantinib | Phase 2-Cabozantinib + Erlotinib |
|---|---|---|---|---|---|---|---|
| Started | 3 | 15 | 17 | 15 | 14 | 15 | 13 |
| Completed | 3 | 14 | 17 | 15 | 14 | 15 | 13 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Treatment duration was defined as the number of days from the first dose to the last dose (measured in weeks), including any days of treatment interruption that occurred before the last dose of study drug.
| Weeks | Phase 1 - Cohort 1 | Phase 1 - Cohort 2A | Phase 1 - Cohort 2B | Phase 1 - Cohort 3A | Phase 1 - Cohort 4A |
|---|---|---|---|---|---|
| Cabozantinib (XL184) | 4.43 (3.0 to 7.1) | 8.14 (2.1 to 143.6) | 8.00 (0.4 to 156.7) | 17.00 (6.1 to 80.3) | 20.07 (4.9 to 57.0) |
| Erlotinib | 6.57 (5.0 to 9.0) | 10.29 (4.1 to 146.3) | 10.00 (2.4 to 158.7) | 22.00 (8.9 to 84.3) | 22.07 (6.9 to 54.7) |
Objective Response Rate is defined as the number of participants for whom the best overall response is complete (CR) or partial response (PR) confirmed by repeat assessments no less than four weeks after the criteria for the initial response were first met.
| Participants | Phase 2 - ARM 1, Cabozantinib ALONE | Phase 2 - ARM 2, Cabozantinib + Erlotinib |
|---|---|---|
| Phase 2: Objective Response Rate (ORR) | 1 | 0 |
DOR was defined as the time interval from the first documentation of CR or PR to the earlier of the first documentation of definitive disease progression or death from any cause.
| Weeks | Phase 2 - ARM 1, Cabozantinib ALONE | Phase 2 - ARM 2, Cabozantinib + Erlotinib |
|---|---|---|
| Phase 2: Duration of Response (DOR) in Participants With a CR or PR | NA (NA to NA) | — |
Progression-free survival is defined as the time from first dose of cabozantinib to disease progression per protocol-defined criteria or death due to any cause, whichever occurs first.
| months | Phase 2 - ARM 1, Cabozantinib ALONE | Phase 2 - ARM 2, Cabozantinib + Erlotinib |
|---|---|---|
| Phase 2: Progression-Free Survival (PFS) | 1.91 (1.64 to 7.06) | 3.94 (1.54 to 7.26) |
Collected over From initial dose through final study visit up to 231 weeks (Phase 1: 159 weeks + Phase 2: 72 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1 - Cohort 1 | — | 1/3 (33.3%) | 3/3 (100%) |
| Phase 1 - Cohort 2A | — | 7/15 (46.7%) | 15/15 (100%) |
| Phase 1 - Cohort 2B | — | 8/17 (47.1%) | 17/17 (100%) |
| Phase 1 - Cohort 3A | — | 8/15 (53.3%) | 15/15 (100%) |
| Phase 1 - Cohort 4A | — | 7/14 (50%) | 14/14 (100%) |
| Phase 2 - ARM 1, Cabozantinib ALONE | — | 5/15 (33.3%) | 15/15 (100%) |
| Phase 2 - ARM 2, Cabozantinib + Erlotinib | — | 11/13 (84.6%) | 12/13 (92.3%) |
| Event | Phase 1 - Cohort 1 | Phase 1 - Cohort 2A | Phase 1 - Cohort 2B | Phase 1 - Cohort 3A | Phase 1 - Cohort 4A | Phase 2 - ARM 1, Cabozantinib ALONE | Phase 2 - ARM 2, Cabozantinib + Erlotinib |
|---|---|---|---|---|---|---|---|
| DEHYDRATIONMetabolism and nutrition disorders | 1/3 | 0/15 | 2/17 | 0/15 | 1/14 | 0/15 | 3/13 |
| DIARRHOEAGastrointestinal disorders | 0/3 | 1/15 | 1/17 | 2/15 | 0/14 | 0/15 | 2/13 |
| ABDOMINAL PAINGastrointestinal disorders | 0/3 | 0/15 | 0/17 | 0/15 | 2/14 | 0/15 | 0/13 |
| PNEUMONIAInfections and infestations | 0/3 | 0/15 | 1/17 | 2/15 | 2/14 | 1/15 | 1/13 |
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 0/3 | 1/15 | 0/17 | 1/15 | 2/14 | 2/15 | 1/13 |
| VOMITINGGastrointestinal disorders | 0/3 | 0/15 | 1/17 | 2/15 | 0/14 | 0/15 | 1/13 |
| BACK PAINMusculoskeletal and connective tissue disorders | 0/3 | 0/15 | 2/17 | 1/15 | 0/14 | 0/15 | 0/13 |
| NEUTROPENIABlood and lymphatic system disorders | 0/3 | 0/15 | 0/17 | 0/15 | 1/14 | 0/15 | 1/13 |
| ACUTE MYOCARDIAL INFARCTIONCardiac disorders | 0/3 | 0/15 | 0/17 | 0/15 | 0/14 | 0/15 | 1/13 |
| LARGE INTESTINE PERFORATIONGastrointestinal disorders | 0/3 | 0/15 | 0/17 | 0/15 | 0/14 | 0/15 | 1/13 |
| Event | Phase 1 - Cohort 1 | Phase 1 - Cohort 2A | Phase 1 - Cohort 2B | Phase 1 - Cohort 3A | Phase 1 - Cohort 4A | Phase 2 - ARM 1, Cabozantinib ALONE | Phase 2 - ARM 2, Cabozantinib + Erlotinib |
|---|---|---|---|---|---|---|---|
| DIARRHOEAGastrointestinal disorders | 3/3 | 14/15 | 13/17 | 13/15 | 13/14 | 9/15 | 10/13 |
| FATIGUEGeneral disorders | 3/3 | 9/15 | 9/17 | 10/15 | 10/14 | 13/15 | 10/13 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 3/3 | 1/15 | 1/17 | 3/15 | 1/14 | 1/15 | 1/13 |
| NAUSEAGastrointestinal disorders | 2/3 | 8/15 | 8/17 | 12/15 | 9/14 | 9/15 | 7/13 |
| DECREASED APPETITEMetabolism and nutrition disorders | 2/3 | 7/15 | 11/17 | 10/15 | 11/14 | 8/15 | 5/13 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 2/3 | 1/15 | 0/17 | 1/15 | 2/14 | 0/15 | 0/13 |
| HYPOMAGNESAEMIAMetabolism and nutrition disorders | 2/3 | 4/15 | 2/17 | 6/15 | 5/14 | 2/15 | 4/13 |
| DRY SKINSkin and subcutaneous tissue disorders | 2/3 | 4/15 | 1/17 | 1/15 | 4/14 | 6/15 | 1/13 |
| RASHSkin and subcutaneous tissue disorders | 0/3 | 9/15 | 7/17 | 6/15 | 4/14 | 3/15 | 4/13 |
| DYSGEUSIANervous system disorders | 0/3 | 3/15 | 4/17 | 8/15 | 6/14 | 3/15 | 3/13 |
| Age, Categorical(Participants) | Phase 1-Cohort 1 | Phase 1-Cohort 2A | Phase 1-Cohort 2B | Phase 1-Cohort 3A | Phase 1-Cohort 4A | Phase 2-cabozantinib | Phase 2-cabozantinib + Erlotinib | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 8 | 12 | 12 | 7 | 12 | 7 | 60 |
| >=65 years | 1 | 7 | 5 | 3 | 7 | 3 | 6 | 32 |
| Age, Continuous(years) | Phase 1-Cohort 1 | Phase 1-Cohort 2A | Phase 1-Cohort 2B | Phase 1-Cohort 3A | Phase 1-Cohort 4A | Phase 2-cabozantinib | Phase 2-cabozantinib + Erlotinib | Total |
|---|---|---|---|---|---|---|---|---|
| Median | 56.1 (50 to 79) | 61.6 (30 to 77) | 61.4 (37 to 88) | 57 (35 to 74) | 64.5 (46 to 85) | 54.7 (36 to 74) | 64.8 (44 to 78) | 59.8 (30 to 88) |
| Sex: Female, Male(Participants) | Phase 1-Cohort 1 | Phase 1-Cohort 2A | Phase 1-Cohort 2B | Phase 1-Cohort 3A | Phase 1-Cohort 4A | Phase 2-cabozantinib | Phase 2-cabozantinib + Erlotinib | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 3 | 9 | 13 | 10 | 9 | 12 | 7 | 63 |
| Male | 0 | 6 | 4 | 5 | 5 | 3 | 6 | 29 |
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2008 to primary completion in Aug 2012, 53 months.
Results were first posted in Jan 2026, 13 years 5 months after primary completion.
Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 53 months is close to that.
Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabozantinib
Carcinoma, Non-Small-Cell Lung →